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Abstract
Background: Chronic hepatitis B virus (HBV) infection represents a serious global health problem and resistance to
lamivudine (LAM) has become a serious clinical challenge. Previous rescue therapy for the treatment of chronic
LAM-resistant hepatitis B infected patients included switching to entecavir (ETV) and adding adefovir (ADV) or
tenofovir (TFV). At present, switching to ETV is not recommended for rescue therapy for LAM-resistant chronic
hepatitis B (CHB). The aim of this report was to determine whether add-on ADV was a superior rescue strategy in
the treatment of CHB patients with LAM resistance.
Methods: We searched Medline/PubMed, EMBASE, Web of Knowledge, and the Cochrane Library. Relative risks
(RRs) of virologic response, virologic breakthrough, normalization of serum alanine aminotransferase (ALT) levels
and HBeAg seroconversion rates were studied. Factors predicting virologic response, standardized mean differences
(SMD) in HBV DNA levels and safety were reviewed.
Results: Six eligible trials (451 patients in total) were included in the analysis. The rate of virologic breakthrough in
the ETV group was higher than that in the LAM plus ADV group. There were no statistical differences in virologic
response, ALT normalization and HBeAg seroconversion in either group 48 weeks post treatment. LAM plus ADV
combination therapy produced faster and greater HBV DNA reduction rates 24 weeks post therapy compared to
ETV monotherapy. HBV DNA baseline levels and the initial virologic response (IVR) were predictive of the virologic
response. Additionally, combination therapy or monotherapy were both well tolerated.
Conclusions: LAM plus ADV combination therapy was more effective and produced longer-lasting effects than
switching to ETV monotherapy in treating CHB patients with LAM resistance. However, considering the practical benefits
and limitations of ADV, individualized therapy will be needed in patients with prior history of LAM resistant infections.
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Background
Chronic hepatitis B virus infection (HBV) poses a serious
global health problem based on the approximately 350
million individuals suffering from chronic hepatitis B
(CHB) infection worldwide [1]. Approximately 1 million
patients die of liver failure, cirrhosis and hepatocellular
carcinoma (HCC) as a result of HBV infection each year
[2]. Studies have demonstrated that the risk of liver disease
progression in patients with CHB is associated with ele-
vated HBV DNA levels [3,4]. Therefore, the goal of ther-
apy for CHB patients is to delay or prevent progression of
liver disease by suppressing long-term HBV DNA replica-
tion [5]. Currently available antiviral drugs include inter-
feron-alpha (INFa) and nucleos(t)ide analogue(NA)
polymerase inhibitors (lamivudine, adefovir, entecavir, tel-
bivudine and tenofovir). Treatments include individualized
single-agent or combination therapies. Evidence-based
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ment of CHB reduced the risk of long-term complications
and improved patient survival [6,7]. Lamivudine (LAM)
was the first nucleoside analog inhibitor to be approved
for treatment of CHB infection and has been used widely
in the treatment of CHB patients. However, a major short-
coming of LAM-based therapies is the development of
drug resistant strains that develop with increasing fre-
quency with treatment duration. The rate of LAM resis-
tance is 24% after 1 year and approximately 70% after 5
years [8]. Furthermore, LAM resistance leads to the
attenuation of HBV suppression and even causes hepatitis
flare ups, hepatic decompensation and increased mortality
rates [9], thereby posing a serious clinical challenge.
Previous rescue therapy for CHB patients with LAM
resistance included switching to entecavir (ETV) and add-
ing adefovir (ADV) or tenofovir (TFV) [9]. ADV-based
therapies have been shown to be efficacious and safe for
up to 5 years in HBeAg positive and negative patients
[10,11]. However, sequential ADV monotherapy used as a
LAM rescue therapy for the treatment of LAM resistant
strains may result in an increased rate of multidrug-resis-
tant HBV isolates. As a rescue therapy, LAM plus ADV
combination therapy is superior to ADV monotherapy,
resulting in effective viral suppression and a reduced risk
of developing genotypic resistance [12,13]. ETV is a more
potent antiviral agent with a high genetic barrier and
induces a significant decline in viral loads in both HBeAg-
positive and -negative treatment-naïve patients [14,15].
Compared to ADV in the treatment of nucleoside-naïve
HBeAg-positive patients, ETV led to a more rapid and sig-
nificant decrease in HBV DNA [16]. As a rescue therapy
for CHB patients with LAM resistance, ETV monotherapy
resulted in continued viral suppression and biochemical
and serologic responses; however, sequential ETV therapy
resulted in a 5-year cumulative probability of genotypic
ETV resistance of 51% [17]. The updated 2009 American
Association for the Study of Liver Disease (AASLD)
Guidelines and the European Association for the Study of
the Liver (EASL) Guidelines indicated that ETV was not
the optimal treatment option and recommended adding
ADV to treat CHB patients with LAM resistance if TDF
was not available [18,19].
Much less is known about the efficacy of LAM plus
ADV combination therapy versus a switch to ETV
monotherapy as a rescue for CHB patients resistant to
LAM. Recently, a number of studies have suggested dif-
ferences in the efficacy between combination therapy
and monotherapy since there are no evidence-based
conclusive results. The purpose of the study described
here was to systematically review and meta-analyze all
published drug-based studies designed to treat CHB
patients with LAM resistance and the use of LAM add-
on ADV combination therapy (or ETV monotherapy)
for the treatment of disease.
Methods
Literature search
Medline/PubMed, EMBASE, Web of Knowledge and the
Cochrane Library were searched for relevant articles
through March 24
th, 2011 without language limitation.
The search was designed using the key words “adefovir”,
“lamivudine”, “entecavir”, “lamivudine resistance”, “lamivu-
dine refractory” or “lamivudine failure”. We obtained full
articles and abstracts for all potentially relevant trials and
the reference lists from retrieved documents were also
searched. To maximize data requisition, we contacted
authors whose articles contained insufficient information.
Inclusion and exclusion criteria
T h ef o l l o w i n gi n c l u s i o nc r i t e r i aw e r eu s e d :( 1 )ar a n d o -
mized control trial-, cohort- or case-control-based study
designs, (2) study population consisting of CHB patients
with LAM resistance, and (3) intervention therapies con-
sisting of LAM plus ADV versus ETV monotherapy.
Patients were excluded if they (1) were not adults, (2) were
pregnant, (3) infected with HBV strains resistant to drugs
other than LAM, (4) co-infected with either hepatitis C,
hepatitis D virus or human immunodeficiency virus (HIV),
(5) presented with serious concurrent medical illness
including concomitant renal failure, evidence of HCC or
organ transplantation history, or (6) use of immunomodu-
latory drugs within the preceding 6 months. Data were not
included in the meta-analysis if we could not gain suffi-
cient statistical information.
Efficacy measures
The primary efficacy end point was virologic response,
defined as the proportion of patients with undetectable
HBV DNA levels. Secondary end points included mean
reduction of HBV DNA levels; virologic breakthrough,
defined as an increase in serum HBV DNA by ≥ 1l o g 10
IU/ml or 1 log10 copies/ml above the nadir on treatment
and biochemical response, defined as normalization of
serum alanine aminotransferase (ALT) levels, HBeAg sero-
conversion, factors predicting virologic response and a
drug safety evaluation designed to capture occurrence of
adverse events.
Data extraction
Two authors (Yun-Jian Sheng and Jun-Ying Liu) inde-
pendently extracted the data using a pre-designed data
extraction form. The following data were recorded: (1)
the number of patients in respective studies, (2) details
of the study design, (3) patient characteristics, (4) treat-
ment doses and duration and (5) outcome measures
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resolved with the assistance of an arbiter (Peng Hu)
when necessary.
Study quality
The quality of each study was assessed based on follow-
ing criteria: (1) RCTs were assessed using the
QUOROM guidelines as well as using the Jadad scale
[20], (2) cohort and case-control studies had to meet
the case matched by the patient’s characteristics, (3) the
studies selected had to have well-defined inclusion and
exclusion criteria for patients and clear definitions of
treatment responses. Discrepancies were resolved with
the assistance of an arbiter (Peng Hu) when necessary.
Statistical analysis
Outcomes were analyzed on an intent-to-treat basis.
Meta-analysis was performed using fixed effect or ran-
dom-effect methods, depending on the absence or pre-
sence of significant heterogeneity. Statistical heterogeneity
between trials was evaluated by the chi-square and I-
square (I
2) tests, with significance set at P <0 . 1 0 .I nt h e
absence of statistically significant heterogeneity, the fixed-
effect method was used to combine the results. When het-
erogeneity was confirmed (P < 0.10), the random-effect
method was used. We used the relative risk (RR) of the
main dichotomous outcomes as the measure of efficacy.
The 95% confidence interval (CI) for the combined RR
was also provided. Continuous outcomes were presented
as a standardized mean difference (SMD) because one
study reported a mean HBV DNA reduction using log10
IU/ml and other studies used log10 copies/ml [21-23]. The
overall effect was tested using z scores calculated by Fish-
er’s z transformation, with significance set at P <0 . 0 5 .
Data analysis was carried out with the use of Review
Manager Software 5.0 (Cochrane Collaboration, Oxford,
United Kingdom).
Results
Search results and characteristics
We identified 1,622 citations via electronic searches,
from which 6 were selected describing treatment of CHB
involving 451 patients (225 treated with combination
LAM plus ADV and 226 treated with ETV monotherapy)
(Figure 1) [21-26]. Of the studies identified, three were
RCTs [22,23,25]; one study [23] was published in Chinese
and two published in English. Four studies [21-24] were
published in full-text form and two [25,26] were pub-
lished in abstract form. Because we did not gain sufficient
statistical information from the data presented in abstract
form, these two studies were not included in our analyses
[27,28], and data presented in the Kim et al. study [24]
(with the exception of virologic breakthrough) were not
included in the meta-analysis. The respective studies uti-
lized are summarized in Table 1.
Study quality
Quality assessment of the respective studies analyzed
demonstrated that the RCTs had Jadad scores that ran-
ged between1-5. Two full manuscripts [22,23] and one
abstract [25] were RCTs and described withdrawn, but
they did not describe the method of randomization in
detail; these three studies received Jadad scores of 2. All
trials had defined inclusion and exclusion criteria for
patients and clear definitions of the treatment responses.
In addition, all study populations had comparable base-
line characteristics between the LAM plus ADV combi-
nation and ETV monotherapy groups.
Virologic response
The rate of undetectable HBV DNA levels was 72.7% and
54.5% in both the ADV add-on LAM group and the ETV
group 48 weeks post treatment in the Kim et al.s t u d y( P
= 0.103) [24]. Analysis of the 5 trials included in the meta-
analysis [21-23,25,26] showed undetectable HBV DNA
levels in the LAM plus ADV group in 41.3% of patients
compared to 40.1% of patients in the ETV group 48 weeks
post treatment. Chi- and I square (I
2) heterogeneity tests
were assessed revealing no significant differences between
treatment groups [Chi
2 = 2.82, df = 4 (P = 0.59); I
2 = 0%];
a summary estimate of the relative risk of LAM plus ADV
versus ETV treatments using a fixed-effects approach. The
rate of undetectable HBV DNA levels was not significant
between groups [RR = 1.11, 95%CI (0.89, 1.37), P =0 . 3 6 ]
(Figure 2).
Mean HBV DNA reduction levels
Among three studies [21-23], chi- and I square (I
2)a n a -
lyses identified significant heterogeneity in HBV DNA
levels between the treatment groups 12 [Tau2 = 0.16;
Chi
2 =8 . 2 4 ,d f=2( P =0 . 0 2 ) ;I
2 = 76%] and 48 weeks
post treatment [Tau2 = 0.16; Chi
2 =7 . 3 5 ,d f=2( P =
0.03); I
2 = 73%]. A summary estimate of the SMD of the
LAM plus ADV versus the ETV group using a random-
effects approach identified a reduction in the HBV DNA
SMD of 0.26 [ 95%CI (-0.26, 0.78), P = 0.33] (Figure 3)
and 0.46 [ 95%CI (-0.07, 0.99), P = 0.09] (Figure 4) at 12
and 48 weeks, respectively. Heterogeneity was assessed
and not found to be significant 24 weeks post treatment.
A summary estimate of the SMD of LAM plus ADV ver-
sus ETV using a fixed-effects approach identified an
SMD reduction of HBV DNA of 0.44 [95%CI (0.18, 0.71),
P = 0.0009] (Figure 5). Furthermore, among three other
studies not included in this meta-analysis, Lee et al.[ 2 6 ]
found that the mean reduction in serum HBV DNA at 48
and 72 weeks post treatment was similar between the
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and -3.0 vs.- 3 . 7l o g 10 copies/ml). However, 96 weeks
post treatment, significant reductions were observed in
the ADV combination group (-2.4 vs.- 4 . 7l o g 10 copies/
ml, P = 0.003). Kim et al. [24] reported that the ADV
combination group had a significant reduction in HBV
DNA levels compared to the ETV treatment group 24
weeks post treatment [-4.17 vs. -2.89 (P = 0.003) log10
copies/ml].
Biochemical response
The ALT normalization rates were 74.3% and 75.0% for
patients in the ADV add-on LAM group and ETV
groups; respectively, 24 weeks post treatment in the
Kim et al. study (P > 0.05) [24]. However, based on the
chi-square and I-square (I
2)a n a l y s e sc a r r i e do u ti nt h e
meta-analysis, significant differences in ALT normaliza-
tion rates were not detected [21-23,26] [Chi
2 = 2.43,
df = 3 (P =0 . 4 9 ) ;I
2 = 0%]; a summary estimate of the
relative risk of LAM plus ADV versus ETV using a
fixed-effects approach demonstrated that the rate of
ALT normalization was not significant between groups
48 weeks post treatment [RR = 1.08, 95%CI (0.96, 1.21),
P = 0.23] (Figure 6).
Virologic breakthrough
Based on the chi-square and I square (I
2) analyses, sig-
nificant differences in heterogeneity were not observed
between treatment groups [Chi
2 = 3.64, df = 4 (P =
0.46); I
2 = 0%]; a summary estimate of the relative risk
of LAM plus ADV versus ETV alone using a fixed-
effects approach demonstrated that the rate of virologic
breakthrough was higher in the ETV group 48 weeks
post treatment [RR = 0.16, 95%CI (0.06, 0.39), P <
0.0001] (Figure 7).
HBeAg seroconversion
Only 3 studies examined in this analysis reported
HBeAg seroconversion rates 48 weeks post treatment
[21,24,27]. The rate of HBeAg seroconversion was
higher in the LAM plus ADV combination therapy
group than that observed for patients in the ETV group
described by Kim et al. (38.9% vs. 0%), but no difference
was observed in the Chung et al. study (31.3% vs. 68.8%,
P = 0.229). Using the chi-square and I square (I
2)a n a -
lyses on the data examined for the meta-analysis
[22,23,26] described here, significant differences in het-
erogeneity were not observed [Chi
2 =3 . 9 1 ,d f=2( P =
0.14); I
2 = 49%]; a summary estimate of the relative risk
1622citations collected
16 clinical studies
8 studies were excluded 
based on  study contents  
18 articles underwent 
Full-text review
1604 citations rejected
2 articles were reviews
6 studies of RCTs, NRCTs 
were included
2articles without sufficient 
information was excluded
Figure 1 Map of the literature search and selection process.
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Page 4 of 10Table 1 Characteristics of the included clinical trials in this study
Study Location Study
design
Sample
size
(n)
Sex (M/F)
(n)
Age
(yrs)
HBeAg
(+)/(-)
(n)
LAM-resistance
mutations at baseline
(LAM+ADV) / ETV (n)
Regimen Therapy
period
LAM+ADV
vs. ETV
Baseline
ALT
(IU/L)
LAM
+ADV
vs. ETV
HBVDNA level
LAM+ADV vs. ETV
The
detection
limit
of HBV DNA
LAM
+ADV
ETV LAM
+ADV
ETV LAM
+ADV
vs. ETV
LAM
+ADV
ETV LAM+ADV ETV
Pellicelli
2009
Italy RCTs 20 42 NA NA Mean
(SD):
47 (11)
vs. 48 (9)
NA
(NS)
NA LAM 100
mg/d +
ADV 10
mg/d
1.0
mg/d
48 weeks
vs. 48 weeks
NA Mean (SD) (log10 IU/
ml):
5 (1.0) vs. 4.63 (1.3)
NA
Qiu
2009
China RCTs 30 30 NA NA NA 15/15 16/
14
NA LAM 100
mg/d +
ADV 10
mg/d
1.0
mg/d
48 weeks
vs. 48 weeks
Mean
(SD):
141.1
(58.2)
vs. 145.7
(61.9)
Mean (SD) (log10
copies/ml):
7.78 (2.62) vs.7.82
(2.32)
< 500
copies/ml
Ryu
2010
Korea RCTs 47 45 34/13 38/
7
Median
(rang):
47 (20-
68)
vs.4 1
(21-60)
39/8 42/
3
M204I:14/15; L180M:1/0;
M204I+M204V:0/1; M204I
+L180M:8/9
M204V+L180M:14/13
M204I+M204V+L180M:10/
7
LAM 100
mg/d +
ADV 10
mg/d
1.0
mg/d
Median (rang),
months:
12 (12-24)
vs. 15 (12-27)
Median
(range):
143 (26-
1096)
vs. 102
(17-677)
Median (rang) (log10
copies/ml):
7.61 (5.19-9.46)
vs.7.10 (5.43-9.47)
< 300
copies/ml
Kim
2010
Korea Cohort 36 24 25/11 21/
3
Mean
(SD):
46.8
(10.4)
vs. 46.9
(8.7)
20/16 18/
6
M204I or M204I+L180M:
24/11
M204V+L180M: 12/13
LAM 100
mg/d +
ADV 10
mg/d
1.0
mg/d
24 months
vs.24 months
Mean
(SD):
227.6
(267.8)
vs. 136.3
(134.2)
Mean (SD) (log10
copies/ml):
6.43 (1.40) vs. 6.51
(1.54)
< 300
copies/ml
Lee
2010
Korea Cohort 48 33 NA
(NS)
NA
(NS)
NA (NS) 41/7 30/
3
NA LAM 100
mg/d +
ADV 10
mg/d
1.0
mg/d
96 weeks
vs. 96 weeks
NA (NS) NA (NS) < 140
copies/ml
Chung
2011
Korea Cohort 44 52 35/9 33/
19
Mean
(SD):
53.7
(10.5)
vs. 50.0
(10.4)
26/18 33/
19
M204V+ L180M: 18/21
M204I+ L180M: 9/9
M204V/I+ L180M: 2/5
M204I: 14/17
M204V/I+ L180M+ V173L:
1/0
LAM 100
mg/d +
ADV 10
mg/d
1.0
mg/d
48 weeks
vs. 48 weeks
Mean
(SD):
151 (125)
vs. 193
(185)
Mean (SD) (log10 IU/
ml):
6.86 (1.17) vs. 6.81
(1.03)
< 50 IU/ml
NA: not available; NS: not significant; iLAM: lamivudine; ADV: adefovir; ETV: entecavir; SD: Standard Deviation; RCTs: randomized controlled trials.
S
h
e
n
g
e
t
a
l
.
V
i
r
o
l
o
g
y
J
o
u
r
n
a
l
2
0
1
1
,
8
:
3
9
3
h
t
t
p
:
/
/
w
w
w
.
v
i
r
o
l
o
g
y
j
.
c
o
m
/
c
o
n
t
e
n
t
/
8
/
1
/
3
9
3
P
a
g
e
5
o
f
1
0of LAM plus ADV versus ETV alone using a fixed-
effects approach demonstrated that the rate of HBeAg
seroconversion was not significant between groups 48
weeks post treatment [RR = 0.51, 95%CI (0.19, 1.38),
P = 0.19] (Figure 8).
Factors predicting the virologic response
Two studies described factors predictive of the virologic
response in the different treatment groups [21,22]. Fol-
lowing multivariate analysis, independent parameters
related to virologic responses were baseline ALT levels
[odds ratio (OR), 1.003; 95% CI, (1.000, 1.006); P = 0.026]
and baseline HBV DNA levels [OR, 0.495; 95% CI, (0.298,
0.823); P = 0.007] [22]. Another study demonstrated that
baseline HBV DNA levels [OR, 0.304; 95% CI, (0.203,
0.457); P = 0.001] and the initial virologic response (IVR)
[OR, 5.928; 95% CI, (2.880, 12.20); P = 0.001] were pre-
dictive of the virologic response [21]. Baseline HBV DNA
levels were a critical parameter for predicting the virolo-
gic response and CHB patients with lower baseline HBV
DNA levels presented with better virologic responses.
Safety
Kim et al.[ 2 4 ]r e p o r t e dt h a t1p a t i e n ti nt h eE T V
monotherapy group experienced severe abdominal pain,
nausea and diarrhea after 1 month of rescue treatment
and treatment was therefore discontinued. One patient
presented with elevated serum creatinine levels in the
LAM plus ADV group. After modification of the ADV
dose, serum creatinine levels declined. Another study
reported that renal function was normal during the time
of rescue treatment [23].
Discussion
Over the past two decades, treatment of CHB has greatly
improved with the availability of nucleos(t)ide analogs.
The sustained suppression of serum HBV DNA to very
low or undetectable levels has been associated with the
prevention liver disease progression and inhibition of the
development of long-term complications [6,7,29]. How-
ever, drug-resistance has been a serious clinical challenge
to CHB treatment, especially for LAM-based therapies
since it was the first widely used antiviral drug. Insuffi-
cient antiviral efficacy caused by drug resistance has
resulted in attenuated viral suppression that may lead to
significant clinical deterioration [9,30]. As a rescue ther-
apy for LAM-resistant patients, previous treatment stra-
tegies have included add-on ADV and a switch to ETV
or TFV [9]. However, ETV monotherapy in patients with
LAM resistance is not currently recommended [18,19],
although in some counties where TFV is not available or
A D Vi sc o s tp r o h i b i t i v e ,as w i t c ht oE T Vi sc o m m o n l y
carried out as a means of treating patients with LAM
resistance. Currently, some studies have carried out
Figure 2 Effect of LAM + ADV vs. ETV on virologic response 48 weeks post treatment.
Figure 3 Effect of LAM + ADV vs. ETV on the mean reduction of HBV DNA 12 weeks post treatment.
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respective rescue strategies. The aim of this analysis was
arrive at an evidence-based conclusion based on available
data regarding the efficacy of both rescue strategies.
Studies have shown that switching to ETV monother-
apy for the treatment of CHB patients with LAM resis-
tance was superior in maintaining viral suppression
compared to continued LAM therapy [31,32]. However,
LAM mutations conferring LAM resistance have pre-
viously been shown to result in reduced susceptibility to
ETV in vitro [33] and ETV exerted positive selective
pressure on LAM-resistant mutants in vivo [34]. Substi-
tutions resulting in mutations at rtL180M/rtM204V in
strains isolated from patients in the ETV group were
treated as a consequence of LAM resistance may have
resulted in the selection of strains with mutations at posi-
tions rtI169T, rtS202I/G, rtT184G or rtM250V. Substitu-
tions at rtS202I/G, rtT184G and rtM205v were found in
strains from patients in the ETV group in this study
[21,24]. The cumulative probability of genotypic ETV
resistance developing over 5 years was 51% in LAM resis-
tant patients [17]. Studies also have shown that add-on
ADV therapy for CHB patients with LAM resistance led
to effective viral suppression [12,13,35] and patients
receiving add-on ADV had a lower risk of developing
genotypic resistance [12,13,35]. In our study, the rate of
virologic breakthrough in the ETV group was higher
than that in the LAM plus ADV group and Lee et al. [26]
found that there was a significant reduction of HBV
DNA in the LAM plus ADV group 96 weeks post treat-
ment (P = 0.003). There were no statistical differences in
the virologic response, ALT normalization and HBeAg
seroconversion rates in either group 48 weeks post treat-
ment. In previous studies [31,32,36,37], HBV DNA was
undetectable 48 weeks post treatment in 21%-33.3% of
patients after switching to ETV and undetectable in 35%-
68% of patients after adding ADV to LAM treatment,
which is inconsistent with data presented in this study.
We speculated that differences in the HBV DNA detec-
tion limits, different definitions of baseline levels, regional
g e n o t y p i cd i f f e r e n c ei nH B Vi s o l a t e s ,t h er a t eo fH B e A g
positive and the male to female ration may explain this
difference. Furthermore, we found that LAM plus ADV
combination therapy produced a more rapid and signifi-
cant reduction in HBV DNA levels 24 weeks post treat-
ment (P = 0.0009) compared to levels observed in
patients receiving ETV monotherapy, even though there
were no significant differences observed 48 weeks post
treatment. Because higher HBV DNA loads represented a
greater risk factor for the development of HCC and cir-
rhosis [3,4], the use of LAM plus ADV would be
expected to result in a better clinical outcome than that
observed for ETV only-treated CHB patients presenting
with LAM resistance.
A new and emerging concept in the management of
antiviral resistance is the superiority of add-on therapy
rather than switching therapy as a means of preventing
the development of subsequent multidrug resistant iso-
lates [30]. The rtA181V/T and rtN236T substitutions
have been identified as the primary ADV-resistance
mutations [10]. Substitutions at rtA181 have been found
after virologic breakthrough during LAM therapy in
Figure 4 Effect of LAM + ADV vs. ETV on the mean reduction of HBV DNA 48 weeks post treatment.
Figure 5 Effect of LAM + ADV vs. ETV on the mean reduction of HBV DNA 24 weeks post treatment.
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performed direct comparisons between LAM plus ADV
combination therapy and ETV monotherapy in CHB
patients resistant to both LAM and ADV [38,39]. Com-
pared to CHB patients resistant to LAM alone in our
study (regardless of combination therapy or monother-
apy), the rate of virologic response was lower (16.7% vs.
41.3% in combination therapy, 12.3% vs. 40.1% in ETV
monotherapy). Therefore, although the prevalent muta-
tions at codon 181 were low (< 4% of patients with LAM
resistance) [40-42], pretreatment resistance testing may
be useful to fully characterize the viral variants present as
a means of ensuring no cross-resistance between strains
as a mean of optimizing drug regimens used in the treat-
ment of CHB patients with LAM resistance.
Ryu et al. [22] showed insufficient virologic responses
following ADV add-on LAM therapy in patients with
higher baseline HBV DNA levels. The virologic response
in patients with higher baseline HBV DNA levels (≥ 8
log10 copies/ml) was only 7.1% compared to 66.7% in
patients with a lower baseline HBV DNA levels (5 ≤
HBVDNA < 6 log10 copies/ml) 48 weeks post treatment.
Therefore, ADV add-on therapy may be more effective in
treating LAM-resistant patients with lower baseline HBV
DNA levels. In addition, add-on ADV should be imple-
mented early because earlier addition of ADV at the time
of virologic breakthrough (when the HBV DNA levels are
low and before the development of biochemical break-
throughs) is associated with a significantly better long-
term outcome in terms of HBV DNA suppression, ALT
normalization and development of ADV-resistant HBV
[35].
Ryu et al. further demonstrated that lower baseline
HBV DNA levels and higher ALT levels were predictive
of the virologic response [22] and Chung et al.[ 2 1 ]
demonstrated that a lower viral load, ADV add-on ther-
apy and IVR were independent predictors of favorable
antiviral outcomes in LAM-resistant patients undergoing
rescue therapy. Therefore, the present study suggested
that the roadmap concept should incorporate baseline
HBV DNA levels and IVR. Add-on ADV rescue therapy
could be maintained for LAM-resistant patients with
lower viral loads at baseline and IVR 24 weeks post anti-
viral treatment.
Combination therapy may have harmful effects. The
potential for an increased risk of toxicity must always be
considered when administering combination LAM plus
ADV. In our study, most patients generally tolerated the
Figure 6 Effect of LAM + ADV vs. ETV on ALT normalization 48 weeks post treatment.
Figure 7 Effect of LAM + ADV vs. ETV on virologic breakthrough 48 weeks post treatment.
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Page 8 of 10drug regimens well; only one patient presented with ele-
vated serum creatinine levels following treatment with
LAM plus ADV, and after the ADV dose modification,
serum creatinine levels declined. However, with the pro-
longation of treatment, 8.7% of patients presented with
elevated creatinine levels (> 0.5 mg/dl) [11] and 16% of
patients treated with LAM plus ADV combination ther-
apy developed renal impairment and those with baseline
GFR < 89 ml/min were at highest risk [43]. Short-term
treatment was associated with fewer side effects following
combination therapy in our study.
This systematic review carried out in this report had
some limitations. First, some studies were not RCTs. Sec-
ond, studies included in this systematic review were few
and had small sample sizes. Third, studies published in
abstract form (and some additional studies) did not report
data that could be included in the meta-analysis; therefore,
we could not carry out a deep analysis. Finally, the impor-
tant limitation was publication bias. More high-quality,
well-designed, randomized controlled, multi-center trails
that are adequately powered will clearly be needed to
guide evolving standards of care for treating CHB patients
with LAM resistance.
In conclusion, LAM plus ADV combination therapy was
more effective and longer lasting than switching to ETV
monotherapy in the treatment of CHB patients with LAM
resistance. However, considering the practical benefits and
limitations of ADV therapy, individualized treatment regi-
mens need to be implemented in treating patients with a
history of prior LAM resistance.
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